Yunqing Qiu

机构：National Clinical Research, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, First Affiliated Hospital Zhejiang University, Zhejiang University · ORCID：0000-0003-0899-2019

发表论文 142 篇 · 总被引 12615 次 · h-index 40

代表论文

• Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma (2024 · Journal of Chinese Integrative Medicine · 被引 20)
• The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation (2024 · Nature Communications · 被引 20)
• Dynamic clinical trial success rates for drugs in the 21st century (2025 · Nature Communications · 被引 16)
• Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort (2025 · Antimicrobial Agents and Chemotherapy · 被引 8)
• Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19 (2024 · NEJM Evidence · 被引 8)
• Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma (2024 · BMC Cancer · 被引 7)